ASSEMBLY BIOSCIENCES

Company snapshot

Assembly Biosciences is a biotechnology company dedicated to the development of innovative small molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impa

• 15 active pipeline program(s) linked via ClinicalTrials.gov.
• 14 US patent(s) indexed to this assignee profile.
• 15 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for ASSEMBLY BIOSCIENCES. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for ASSEMBLY BIOSCIENCES.

1. Jun 8, 2026 Clinical update

   ABI-4334-102 — Phase 1

2. Jun 8, 2026 Clinical update

   Vebicorvir (VBR) — Phase 1

3. Jun 8, 2026 Clinical update

   standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI) — Phase 2

4. Jun 5, 2026 Clinical update

   ABI-H2158 Reference Formulation — Phase 1

5. Jun 5, 2026 Clinical update

   ABI-4334 Tablet — Phase 1

View all clinical trial activity →

• What is ASSEMBLY BIOSCIENCES?

  Assembly Biosciences is a pharma organization headquartered in South San Francisco, USA. It trades on NYSE under ticker ASMB. Primary therapeutic focus areas include Chronic Hepatitis B, Recurrent Genital Herpes Simplex Type 2, chronic hepatitis B virus infection (cHBV), Hepatiti

• Is ASSEMBLY BIOSCIENCES publicly traded?

  Yes. ASSEMBLY BIOSCIENCES is listed with ticker ASMB on NYSE per SEC EDGAR records linked on this profile.

• What drugs does ASSEMBLY BIOSCIENCES develop or market?

  We link 10 drug profile(s) where ASSEMBLY BIOSCIENCES is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/assembly-biosciences-inc#company-drugs.

• What are the latest developments for ASSEMBLY BIOSCIENCES?

  In the last 12 months our linked public records show 15 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does ASSEMBLY BIOSCIENCES focus on?

  ASSEMBLY BIOSCIENCES focuses on Chronic Hepatitis B, Recurrent Genital Herpes Simplex Type 2, chronic hepatitis B virus infection (cHBV) based on our analysis of their pipeline programs and drug development activities.